Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
| Title: | Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe |
|---|---|
| Authors: | Germaine Hanquet, Pavla Krizova, Tina Dalby, Shamez N. Ladhani, J. Pekka Nuorti, Kostas Danis, Jolita Mereckiene, Mirjam J. Knol, Brita A. Winje, Pilar Ciruela, Sara de Miguel, Maria Eugenia Portillo, Laura MacDonald, Eva Morfeldt, Jana Kozakova, Palle Valentiner-Branth, Norman K. Fry, Hanna Rinta-Kokko, Emmanuelle Varon, Mary Corcoran, Arie van der Ende, Didrik F. Vestrheim, Carmen Munoz-Almagro, Juan-Carlos Sanz, Jesus Castilla, Andrew Smith, Birgitta Henriques-Normark, Edoardo Colzani, Lucia Pastore-Celentano, Camelia Savulescu |
| Source: | Emerging Infectious Diseases, Vol 28, Iss 1, Pp 137-138 (2022) |
| Publisher Information: | Centers for Disease Control and Prevention, 2022. |
| Publication Year: | 2022 |
| Collection: | LCC:Medicine LCC:Infectious and parasitic diseases |
| Subject Terms: | Streptococcus pneumoniae, pneumococcal infections, 13-valent pneumococcal vaccine, 10-valent pneumococcal vaccine, 15-valent pneumococcal vaccine, 20-valent pneumococcal vaccine, Medicine, Infectious and parasitic diseases, RC109-216 |
| More Details: | We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011–2014 but increased during 2015–2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children 65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution. Serotypes included in the 15-valent PCV represented one third of cases and those in the 20-valent PCVs two thirds of cases in children 65 years of age in 2018. Non-PCV13 serotype increases reduced the overall effect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1080-6040 1080-6059 |
| Relation: | https://wwwnc.cdc.gov/eid/article/28/1/21-0734_article; https://doaj.org/toc/1080-6040; https://doaj.org/toc/1080-6059 |
| DOI: | 10.3201/eid2801.210734 |
| Access URL: | https://doaj.org/article/1f129c2eb667436c9c125a71a66c2441 |
| Accession Number: | edsdoj.1f129c2eb667436c9c125a71a66c2441 |
| Database: | Directory of Open Access Journals |
| ISSN: | 10806040 10806059 |
|---|---|
| DOI: | 10.3201/eid2801.210734 |
| Published in: | Emerging Infectious Diseases |
| Language: | English |